Pancreatic Tumor Markers




Tumor markers are used for determining the effect of the treatment.



αフェトプロテイン  alpha-fetoprotein;

ガラクトシルトランスフェラーゼII  galactosyl transferase II;

癌胎児性抗原  carcinoembryonic antigen (CEA);

感度 ... 感度は疾患のある人のうち検査結果が陽性 とな った人の割合(真陽性率)  sensitivity;

シアル化ルイスA抗原  sialylated Lewis A antigen;

腫瘍マーカ  tumor marker;

特異度 ... 特異度は疾 患 のない人のうち検査結果が陰性となった人 の割合(真陰性率)  specificity;

分画レベル  cutoff level



Tumor markers are substances that are released into the blood circulation by tumor tissues.  When tumor markers are detected from the serum of the patients, they are likely to have tumors.



However, clinical use of tumor markers is limited.


 credit:  Lewis A, Funakoshi


CA-19-9 is sialylated Lewis A antigen that is present in digestive organs and so forth in an extremely small quantity.  This tumor marker has been widely used for pancreatic cancers.  If tumors occur in the pancreas, the antigen rapidly increases and enters the blood stream. 


最も一般的なCA-19-9の分画レベルは37 U/mLであり、感度は81から85%、特異度は81から90%である。CA-19-9のレベルが1000 U/mLを超えると、切除不能な膵臓癌と判定される。

The cutoff level of CA-19-9 for pancreatic cancers is most commonly 37 U/mL.  While the sensitivity of this tumor marker ranges from 81 to 85%, its specificity ranges from 81 to 90%.  When the level of CA-19-9 exceeds 1000 U/mL, the patients are likely to have contracted unresectable pancreatic cancers. 



Tumor markers are not substituted for a histologic diagnosis, but for determining the effect of the treatment.



There are also other pancreatic tumor markers: carcinoembryonic antigen (CEA), alpha-fetoprotein, CA125, and galactosyl transferase II.